close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

10x Genomics, Inc. - Common Stock (NQ:TXG)

12.44 -0.46 (-3.57%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 10x Genomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
10X Genomics Inc-Class A (NASDAQ:TXG) Surprises with Strong Q2 2025 Earnings and Revenue Beat
10X Genomics (TXG) reported strong Q2 2025 earnings, beating revenue and EPS estimates, sparking a 4.68% after-hours stock surge. Revenue hit $172.91M, up 22.8%, with EPS at $0.28 vs. expected loss.... 
Via Chartmill
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Earnings To Watch: 10x Genomics (TXG) Reports Q2 Results Tomorrow
Biotech company 10x Genomics (NASDAQ:TXG) will be reporting results this Thursday after market hours. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence Economy World Trade
PacBio, 10x Genomics, QuidelOrtho, STAAR Surgical, and Clover Health Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after industry bellwether UnitedHealth Group (UNH) slashed its 2025 profit forecast after reporting a significant surge in medical costs, sending... 
Via StockStory
Fortrea, Azenta, Bio-Techne, 10x Genomics, and Amphastar Pharmaceuticals Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after a new trade agreement between the United States and Japan spurred a broad market rally. 
Via StockStory
Topics Stocks World Trade
What's Driving the Market Sentiment Around 10x Genomics?
 
Via Benzinga
Forecasting The Future: 7 Analyst Projections For 10x Genomics
 
Via Benzinga
3 Unprofitable Stocks We’re Skeptical Of
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital... 
Via StockStory
Thermo Fisher, Exact Sciences, Integer Holdings, Revvity, and 10x Genomics Shares Are Falling, What You Need To Know
A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like... 
Via StockStory
Topics Lawsuit World Trade
3 Russell 2000 Stocks with Red Flags
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher... 
Via StockStory
Earnings Scheduled For May 8, 2025
 
Via Benzinga
Acadia Healthcare, 10x Genomics, Amphastar Pharmaceuticals, Myriad Genetics, and QuidelOrtho Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. 
Via StockStory
Topics ETFs Stocks World Trade
Demystifying 10x Genomics: Insights From 8 Analyst Reviews
 
Via Benzinga
Life Sciences Tools & Services Stocks Q1 Results: Benchmarking 10x Genomics (NASDAQ:TXG)
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at life sciences tools & services stocks,... 
Via StockStory
Topics Artificial Intelligence
Delta, Macy's, CECO Environmental, RadNet, and 10x Genomics Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +1.5%, S&P 500 +1.0%) as reports pointed to easing tensions between Israel and Iran. 
Via StockStory
Topics Economy Government Stocks
1 Cash-Producing Stock with Exciting Potential and 2 to Ignore
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
1 of Wall Street’s Favorite Stock with Promising Prospects and 2 to Be Wary Of
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because... 
Via StockStory
Topics Artificial Intelligence
TXG Q1 Earnings Call: Academic Funding Uncertainty Drives Guidance Withdrawal and Cost Reductions
Biotech company 10x Genomics (NASDAQ:TXG) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 9.8% year on year to $154.9 million. On the other hand, next quarter’s... 
Via StockStory
Topics Intellectual Property
Cathie Wood's Ark Invest Continues To Offload Tesla As Elon Musk Moves On From Trump Administration
Ark Invest made significant trades in TSLA, TXG, NTLA, DDD, and ADPT. Purchase of TXG and NTLA from ARKG and ARKK funds, and sale of TSLA, DDD, and ADPT from various funds. 
Via Benzinga
Topics Government
Powell, Mayville Engineering, Graham Corporation, Hyster-Yale Materials Handling, and 10x Genomics Shares Skyrocket, What You Need To Know
A number of stocks jumped in the morning session after the major indices rebounded (Nasdaq +2.0%, S&P 500 +1.5%) as President Trump postponed the planned 50% tariff on European Union imports, shifting... 
Via StockStory
Topics Government Stocks World Trade
Cathie Wood Reiterates 'Profound' AI Application In Healthcare As Researchers Discover 'Cancer Survival Outcomes' By Facial Photograph Analysis: Here Are The Stocks That Could Benefit
Cathie Wood underscored the application of AI in the healthcare sector by sharing new research by Mass General Brigham. 
Via Benzinga
Topics Artificial Intelligence
Why 10x Genomics Stock Was Sliding This Week
Via The Motley Fool
Topics Intellectual Property
1 Small-Cap Stock with Exciting Potential and 2 to Turn Down
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
3 Volatile Stocks Walking a Fine Line
A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be costly for those who aren’t prepared. 
Via StockStory
Analyst Expectations For 10x Genomics's Future
 
Via Benzinga
Cathie Wood Says AI Innovation In Healthcare Will Be More 'Profound' Than Autonomous Taxi Networks, Humanoid Robots
Cathie Wood highlights the rising applications of AI and how it is poised to impact the health care space. 
Via Benzinga
Topics Artificial Intelligence
3 Stocks Under $10 Walking a Fine Line
Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts. But that doesn’t mean the underlying businesses are cheap, and we advise caution as... 
Via StockStory
10x Genomics CEO Calls NIH The 'Foundational Jewel' Of Biomedical Progress, Says 40% To 50% Of Revenue Supported By Academic And Government Research Funding — Pulls Full Year Revenue Guidance
10x Genomics Inc. criticized U.S. government budget cuts for academic research, withdrew full-year guidance, and shifted to quarterly forecasts. 
Via Benzinga
10x Genomics’s (NASDAQ:TXG) Q1: Strong Sales But Quarterly Revenue Guidance Significantly Misses Expectations
Biotech company 10x Genomics (NASDAQ:TXG) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 9.8% year on year to $154.9 million. On the other hand, next quarter’s... 
Via StockStory
10x Genomics (TXG) Reports Q1: Everything You Need To Know Ahead Of Earnings
Biotech company 10x Genomics (NASDAQ:TXG) will be announcing earnings results tomorrow after the bell. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today